Unexpected Uterine Cancer: Power Morcellation and Mortality


A study recently published in the Journal of Clinical Oncology reported on the association between power morcellation and mortality in women with unexpected uterine cancer who were undergoing a hysterectomy or myomectomy.

The authors point to clinician and researcher suspicions that power morcellation might have a negative effect on the prognosis of uterine cancer, but actual evidence was lacking, which prompted their research in this study to determine whether hysterectomy or myomectomy procedures that included uncontained power morcellation would prove a negative prognostic factor related to mortality risk in women with cancer of the uterus.

The researchers compiled data on hospital discharges recorded in the New York cancer registry, identifying 334 women diagnosed with occult uterine sarcoma, and 843 women diagnosed with occult endometrial carcinoma, all of whom had either a hysterectomy or myomectomy for what clinicians at first believed to be a benign condition. The time frame of the surgeries was October 1, 2003, through December 31, 2013.

Within the cohort, the authors analyzed disease-specific mortality and mortality from all causes in women who had laparoscopic supracervical hysterectomy/laparoscopic myomectomy (LSH/LM), which typically includes uncontained power morcellation. They compared records with those of women who had a supracervical abdominal hysterectomy and total abdominal hysterectomy (TAH), but which did not involve power morcellation. The authors performed multivariable Cox regressions and used the propensity score method to adjust for patient characteristics.

In women who had occult uterine sarcoma, LSH/LM predicted a higher risk of disease-related mortality than TAH did (adjusted hazard ratio [aHR], 2.66, 95% CI, 1.11 to 6.37; adjusted difference in 5-year disease-specific survival, 219.4%, 95% CI, 235.8% to 23.1%). In those women with leiomyosarcoma, there was an association between LSH/LM and increased risk of mortality stemming from disease when compared with supracervical abdominal hysterectomy (aHR, 3.64, 95% CI, 1.50 to 8.86; adjusted difference in 5-year disease-specific survival, 231.2%, 95% CI, 250.0% to 212.3%) and TAH (aHR, 4.66, 95% CI, 1.97 to 11.00; adjusted difference in 5-year disease-specific survival, 237.3%, 95% CI, 254.2% to 220.3%).

In those women who had been diagnosed with endometrial carcinoma, however, there was no remarkable association between method of surgery and mortality related to disease.

The authors concluded that power morcellation may increase mortality risk in women who have occult uterine sarcoma, especially those diagnosed with occult leiomyosarcoma.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content